ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 355,37
1,00%
Dow Jones
42 964,29
-0,83%
DAX
19 984,32
0,74%
Brent Oil
73,815
1,27%
Bitcoin
94 449,12
-1,29%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Annexon Inc (ANNX)

  7. Annexon Inc (ANNX) Actualités

ANNX

Annexon (ANNX)

Annexon Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ANNX
DateHeureSourceTitreSymboleSociété
19/12/202422h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANNXAnnexon Inc
16/12/202413h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANNXAnnexon Inc
05/12/202400h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
15/11/202400h46Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANNXAnnexon Inc
14/11/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANNXAnnexon Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ANNXAnnexon Inc
15/10/202420h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANNXAnnexon Inc
16/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ANNXAnnexon Inc
12/08/202422h59Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANNXAnnexon Inc
07/06/202403h57Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANNXAnnexon Inc
16/04/202415h00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ANNXAnnexon Inc
15/02/202402h46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANNXAnnexon Inc
12/02/202422h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANNXAnnexon Inc
23/01/202423h00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANNXAnnexon Inc
08/01/202402h00GlobeNewswire Inc.Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesNASDAQ:ANNXAnnexon Inc
27/12/202312h30GlobeNewswire Inc.Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
22/12/202323h28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANNXAnnexon Inc
20/12/202323h27GlobeNewswire Inc.Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockNASDAQ:ANNXAnnexon Inc
20/12/202323h24Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ANNXAnnexon Inc
20/12/202323h10GlobeNewswire Inc.Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointNASDAQ:ANNXAnnexon Inc
20/12/202323h08GlobeNewswire Inc.Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayNASDAQ:ANNXAnnexon Inc
18/12/202322h01GlobeNewswire Inc.Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
22/11/202322h01GlobeNewswire Inc.Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ANNXAnnexon Inc
13/11/202312h30GlobeNewswire Inc.Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
09/11/202312h30GlobeNewswire Inc.Annexon Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
24/10/202312h30GlobeNewswire Inc.Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic AtrophyNASDAQ:ANNXAnnexon Inc
10/10/202312h30GlobeNewswire Inc.Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)NASDAQ:ANNXAnnexon Inc
19/09/202312h30GlobeNewswire Inc.Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
18/09/202322h01GlobeNewswire Inc.Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
07/08/202312h30GlobeNewswire Inc.Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
 Showing the most relevant articles for your search:NASDAQ:ANNX

Dernières Valeurs Consultées

USOTC
VYYRF
Voyageur Pharmaceuticals (PK)
TSXV
ZFR
Zephyr Minerals
COIN
MTHDUSD
Method
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés